Inclisiran not checked

Novartis · KJX839 · PCSK9 inhibitor

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 4 trial completes
Trials
20 active
35 in total · 15 in the EU
Targets
—
None known yet

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
How it’s given
“Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270”In the company’s words, NCT06501443 on ClinicalTrials.gov
Tested for
Hypercholesterolaemia (2 trials), Acute Coronary Syndrome (2 trials), Plaque, Atherosclerotic, Coronary Heart Disease, Hypercholesterolemia, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD) and 5 more
Main trialPhase 4
“This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.”In the company’s words, NCT06501443 on ClinicalTrials.gov
Other names
KJX839 · ALN-PCSSC · Leqvio · PCSK9 inhibitor · siRNA

Other drugs for Hypercholesterolaemia

All 21 drugs for Hypercholesterolaemia

Coming up12

Changes2

Last 90 days

Trials35

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 27 Nov 2026 LATAM LOWERS LDL-C
Phase 4Active, not recruiting 30 Dec 2026 Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Phase 4Active, not recruiting 30 Apr 2027 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Phase 4Not yet recruiting 29 Feb 2028 Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Phase 3Active, not recruiting 9 Jun 2022 Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Phase 3Active, not recruiting 26 Oct 2026 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Phase 3Active, not recruiting 16 Jan 2027 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Phase 3Active, not recruiting 10 May 2027 Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Phase 3Active, not recruiting 3 Feb 2028 Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Phase 3Recruiting 21 Mar 2028 Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Phase 3Recruiting 21 Mar 2028 Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Phase 3Active, not recruiting 16 Apr 2029 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Phase 3Recruiting 25 Mar 2032 Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Phase 2Recruiting 28 Apr 2027 A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Phase 1Recruiting 21 Dec 2026 Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
Phase 4Completed 11 Jun 2024 Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Phase 4Completed 1 Dec 2025 A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
Phase 4Completed 13 Jan 2026 A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Phase 3Completed 2 Mar 2020 A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Phase 3Completed 13 Jan 2023 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Phase 3Completed 13 Feb 2023 Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
Phase 3Completed 15 Sep 2023 A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
Phase 3Completed 30 Oct 2023 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
Phase 3Completed 9 Nov 2023 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Phase 3Completed 2 Apr 2024 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Phase 3Completed 20 Jun 2024 Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
Phase 3Completed 7 Aug 2024 Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
Phase 2Completed 17 Dec 2021 An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
Phase 2Completed 18 Apr 2022 Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Phase 1Completed 18 Oct 2021 Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C
Phase 3Authorised not given Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial
Phase 4Authorised not given The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis
Phase 4Authorised not given Implementation Study of Lipid Management of High-risk Cardiovascular Patients- Semmelweis Lipid Center for High-risk Patients
Phase 4Authorised not given Effect of Inclisiran on LDL-C Levels and Coronary Plaque Burden Assessed by Ultra-High Resolution Photon-Counting CT Angiography
Phase 4Authorised not given Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Inclisiran

Following is part of Solo: you see every change to Inclisiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in